Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

@article{Bodin2005CytochromeP2,
  title={Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.},
  author={L. Bodin and C. Verstuyft and D. Tregouet and A. Robert and L. Dubert and C. Funck-Brentano and P. Jaillon and P. Beaune and P. Laurent-Puig and L. Becquemont and M. Loriot},
  journal={Blood},
  year={2005},
  volume={106 1},
  pages={
          135-40
        }
}
The aim of the study is to explore the contribution of genetic factors related either to drug metabolism (cytochrome P450 2C9) or to drug target (vitamin K epoxide reductase) to variability in the response to acenocoumarol among 222 healthy volunteers after a single oral dose. Associations between a pharmacodynamic index (reduction in factor VII activity and international normalized ratio [INR] change) and several genetic polymorphisms (VKORC1: -4931T>C, -4451C>A, -2659G>C, -1877A>G, -1639G>A… Expand
VKORC1 −1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement
Contribution of CYP2C9 to variability in vitamin K antagonist metabolism
  • A. Daly, B. King
  • Biology, Medicine
  • Expert opinion on drug metabolism & toxicology
  • 2006
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
Pharmacogenetics of oral anticoagulants.
...
1
2
3
4
...